CXCR3 and systemic lupus erythematosus: Another study found that CXCR3−/− NZB/NZW mice exhibited reduced production of total and anti-dsDNA antibodies of the IgG1 subclass but had normal titers of IgG2a and IgG2b antibodies compared to CXCR3+/+ NZB/NZW mice, indicating that therapeutic CXCR3 blockade could be beneficial for only a subgroup of patients with SLE [90].